About Us

HepQuant is a privately-held company with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease. Chief Executive Officer and test inventor Dr. Greg Everson founded the company in 2007 with a small group of investors.

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

The company’s products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process.

We are headquartered at 8110 E. Union Ave, Suite 750, Denver, CO 80237. Phone: (303) 923-2242